Actin vs Sunlight
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Actin
Best for affordable compounded semaglutide with B12 enhancementStarting at $133/mo
Sunlight
Best for patients prioritizing publicly-disclosed compounded GLP-1 pricing ($179/mo sema or $259/mo tirz first-month) with bundled unlimited telehealth visits + free shipping, willing to verify steady-state ongoing pricing during the intakeStarting at $179/mo
Side-by-Side Comparison
| Feature | Actin | Sunlight |
|---|---|---|
| Overall Score | 7.0/10 | ✓7.3/10 |
| Starting Price | ✓$133/mo | $179/mo |
| Editorial Rating | 3.5 ★ /5 | ✓3.7 ★ /5 |
| Features | 2 features | ✓7 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Actin
Pros
- ✓Semaglutide + B12 combination for added energy support
- ✓Transparent pricing — exact cost shown upfront with no hidden fees
- ✓Competitive starting price from $133
Cons
- ✗Semaglutide only — no tirzepatide or liraglutide
- ✗No visible LegitScript or PCAB accreditation
- ✗State availability not disclosed
- ✗Broader platform (hormones, sexual wellness, hair health)
Sunlight
Pros
- ✓$179/mo compounded semaglutide and $259/mo compounded tirzepatide are publicly disclosed (first-month rate) — cost transparency advantage
- ✓LegitScript Certified seal verified verbatim ('Sunlight.com is a LegitScript-certified telehealth platform')
- ✓Unlimited telehealth visits + free shipping bundled into the flat monthly rate
- ✓Patient testimonial documents real-world $1,200/mo → Sunlight cost-disruption (-31 lbs in 4 months on tirzepatide)
- ✓Compounded-GLP-1 focused with explicit semaglutide + tirzepatide product lines
Cons
- ✗Steady-state monthly pricing AFTER the first month is ambiguous — language verbatim is 'starts at $179 per month and tirzepatide at $259 per month for the first month' which could mean either (a) flat $179/$259 ongoing OR (b) higher steady-state with $179/$259 first-month promo. 'Each flat monthly rate includes...' suggests flat ongoing but verify during intake before committing
- ✗Specific legal entity name + state of incorporation NOT publicly disclosed
- ✗Specific partner compounding pharmacy NOT named
- ✗Per-state availability NOT enumerated
- ✗Brand-name GLP-1 lineup (Wegovy/Zepbound/Mounjaro/Ozempic/Foundayo) NOT addressed — compounded only
- ✗Multi-funnel A/B-tested marketing architecture (separate / vs /t3/ landing pages with cookie-based path persistence) is a soft signal of aggressive DTC marketing optimization rather than a clinical-medical-first platform
- ✗Lab work + ongoing-care touchpoints beyond the unlimited-telehealth-visits framing NOT clearly disclosed in marketing copy
Our Verdict
Sunlight edges out Actin with a higher overall score of 7.3/10 and is particularly strong for patients prioritizing publicly-disclosed compounded GLP-1 pricing ($179/mo sema or $259/mo tirz first-month) with bundled unlimited telehealth visits + free shipping, willing to verify steady-state ongoing pricing during the intake. Actin remains a solid alternative, especially if you're looking for affordable compounded semaglutide with B12 enhancement.
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.